Cargando…

Effects of Histone Deacetylase Inhibitor Panobinostat (LBH589) on Bone Marrow Mononuclear Cells of Relapsed or Refractory Multiple Myeloma Patients and Its Mechanisms

BACKGROUND: The aim of this study was to explore the impact of LBH589 alone or in combination with proteasome inhibitor bortezomib on multiple myeloma (MM) cell proliferation and its mechanism. MATERIAL/METHODS: MM cell line U266 and RRMM-BMMNC were treated with different concentrations of LBH589 al...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ma, Yanping, Liu, Wenhua, Zhang, Ling, Jia, Gu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	International Scientific Literature, Inc. 2017
Materias:	Lab/In Vitro Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5674922/ https://www.ncbi.nlm.nih.gov/pubmed/29080899 http://dx.doi.org/10.12659/MSM.904232

Ejemplares similares

Influence of a novel histone deacetylase inhibitor panobinostat (LBH589) on the growth of ovarian cancer
por: Garrett, Leslie A., et al.
Publicado: (2016)

The Histone Deacetylase Inhibitor LBH589 (Panobinostat) Modulates the Crosstalk of Lymphocytes with Hodgkin Lymphoma Cell Lines
por: Klein, Jan M., et al.
Publicado: (2013)

Molecular Mechanism of the Cell Death Induced by the Histone Deacetylase Pan Inhibitor LBH589 (Panobinostat) in Wilms Tumor Cells
por: Yan-Fang, Tao, et al.
Publicado: (2015)

A phase I trial of panobinostat (LBH589) in patients with metastatic melanoma
por: Ibrahim, Nageatte, et al.
Publicado: (2016)

Combination of Histone Deacetylase Inhibitor Panobinostat (LBH589) with β-Catenin Inhibitor Tegavivint (BC2059) Exerts Significant Anti-Myeloma Activity Both In Vitro and In Vivo
por: Savvidou, Ioanna, et al.
Publicado: (2022)

Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor
por: Hamberg, Paul, et al.
Publicado: (2011)

Combination Therapy with the Histone Deacetylase Inhibitor LBH589 and Radiation Is an Effective Regimen for Prostate Cancer Cells
por: Xiao, Weiwei, et al.
Publicado: (2013)

Panobinostat (LBH589) combined with AM1241 induces cervical cancer cell apoptosis through autophagy pathway
por: Sheng, Bo, et al.
Publicado: (2023)

Sustained Low-Dose Treatment with the Histone Deacetylase Inhibitor LBH589 Induces Terminal Differentiation of Osteosarcoma Cells
por: Cain, Jason E., et al.
Publicado: (2013)

Clinical developments in the treatment of relapsed or relapsed and refractory multiple myeloma: impact of panobinostat, the first-in-class histone deacetylase inhibitor
por: Redic, Kimberly A, et al.
Publicado: (2016)

The histone deacetylase inhibitor, LBH589, promotes the systemic cytokine and effector responses of adoptively transferred CD8+ T cells
por: Lisiero, Dominique N, et al.
Publicado: (2014)

Relationship Between Histone Deacetylase 3 (HDAC3) and Breast Cancer
por: Cui, Zhuhong, et al.
Publicado: (2018)

c-FLIP Degradation Mediates Sensitization of Pancreatic Cancer Cells to TRAIL-Induced Apoptosis by the Histone Deacetylase Inhibitor LBH589
por: Kauh, John, et al.
Publicado: (2010)

DNA microarray profiling of genes differentially regulated by the histone deacetylase inhibitors vorinostat and LBH589 in colon cancer cell lines
por: LaBonte, Melissa J, et al.
Publicado: (2009)

Convection enhanced delivery of panobinostat (LBH589)-loaded pluronic nano-micelles prolongs survival in the F98 rat glioma model
por: Singleton, WG, et al.
Publicado: (2017)

Expression of histone deacetylase (HDAC) family members in bortezomib-refractory multiple myeloma and modulation by panobinostat
por: Cheng, Tiewei, et al.
Publicado: (2021)

The Bcl-2 inhibitor Obatoclax overcomes resistance to histone deacetylase inhibitors SAHA and LBH589 as radiosensitizers in patient-derived glioblastoma stem-like cells
por: Berghauser Pont, Lotte M.E., et al.
Publicado: (2014)

Curcumol Controls Choriocarcinoma Stem-Like Cells Self-Renewal via Repression of DNA Methyltransferase (DNMT)- and Histone Deacetylase (HDAC)-Mediated Epigenetic Regulation
por: Peng, Zheng, et al.
Publicado: (2018)

miR-149-5p Inhibits Vascular Smooth Muscle Cells Proliferation, Invasion, and Migration by Targeting Histone Deacetylase 4 (HDAC4)
por: Zhang, Boya, et al.
Publicado: (2019)

HDAC Inhibition by LBH589 Affects Phenotype and Function of Human Myeloid Dendritic Cells
por: Song, W, et al.
Publicado: (2010)

1,25-Dihydroxyvitamin D3 Prevents Epithelial-Mesenchymal Transition of HMrSV5 Human Peritoneal Mesothelial Cells by Inhibiting Histone Deacetylase 3 (HDAC3) and Increasing Vitamin D Receptor (VDR) Expression Through the Wnt/β-Catenin Signaling Pathway
por: Liu, Kang-Han, et al.
Publicado: (2019)

HDAC Inhibitor LBH589 Suppresses the Proliferation but Enhances the Antileukemic Effect of Human γδT Cells
por: He, Ying, et al.
Publicado: (2020)

EMA Review of Panobinostat (Farydak) for the Treatment of Adult Patients with Relapsed and/or Refractory Multiple Myeloma
por: Tzogani, Kyriaki, et al.
Publicado: (2018)

EMA Review of Panobinostat (Farydak) for the Treatment of Adult Patients with Relapsed and/or Refractory Multiple Myeloma
por: Tzogani, Kyriaki, et al.
Publicado: (2017)

Panobinostat PK/PD profile in combination with bortezomib and dexamethasone in patients with relapsed and relapsed/refractory multiple myeloma
por: Mu, Song, et al.
Publicado: (2015)

Integrated Analysis of Genetic Abnormalities of the Histone Lysine Methyltransferases in Prostate Cancer
por: Zhang, Yangjun, et al.
Publicado: (2019)

LBH589, a deacetylase inhibitor, induces apoptosis in adult T-cell leukemia/lymphoma cells via activation of a novel RAIDD-caspase-2 pathway
por: Hasegawa, H, et al.
Publicado: (2011)

The Role of Panobinostat Plus Bortezomib and Dexamethasone in Treating Relapsed or Relapsed and Refractory Multiple Myeloma: A European Perspective
por: San-Miguel, Jesus F., et al.
Publicado: (2016)

Phase 1 open-label study of panobinostat, lenalidomide, bortezomib + dexamethasone in relapsed and relapsed/refractory multiple myeloma
por: Laubach, Jacob P., et al.
Publicado: (2021)

LBH589, A Hydroxamic Acid-Derived HDAC Inhibitor, is Neuroprotective in Mouse Models of Huntington’s Disease
por: Chopra, Vanita, et al.
Publicado: (2016)

Pooled analysis of the reports of carfilzomib, panobinostat, and elotuzumab combinations in patients with refractory/relapsed multiple myeloma
por: Liu, Liping, et al.
Publicado: (2016)

Panobinostat in combination with bortezomib and dexamethasone in multiply relapsed and refractory myeloma; UK routine care cohort
por: Maouche, Nadjoua, et al.
Publicado: (2022)

Baicalein Inhibits Proliferation of Myeloma U266 Cells by Downregulating IKZF1 and IKZF3
por: Liu, Xiao-Ping, et al.
Publicado: (2018)

Using Prognosis-Related Gene Expression Signature and Connectivity Map for Personalized Drug Repositioning in Multiple Myeloma
por: Zhu, Fang-xiao, et al.
Publicado: (2019)

Prostacyclin Suppresses Twist Expression in the Presence of Indomethacin in Bone Marrow-Derived Mesenchymal Stromal Cells
por: Kemper, Oliver, et al.
Publicado: (2014)

GANT61 and Valproic Acid Synergistically Inhibited Multiple Myeloma Cell Proliferation via Hedgehog Signaling Pathway
por: Zhang, Zhihua, et al.
Publicado: (2020)

Inhibitory Effect of Sirtuin6 (SIRT6) on Osteogenic Differentiation of Bone Marrow Mesenchymal Stem Cells
por: Xiao, Fei, et al.
Publicado: (2019)

Overexpression of Bone Morphogenetic Protein-1 Promotes Osteogenesis of Bone Marrow Mesenchymal Stem Cells In Vitro
por: Su, Zhongping, et al.
Publicado: (2020)

Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat
por: Tate, Chandra R, et al.
Publicado: (2012)

Isoflurane Promotes Non-Small Cell Lung Cancer Malignancy by Activating the Akt-Mammalian Target of Rapamycin (mTOR) Signaling Pathway
por: Zhang, Wenhua, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_gijh3lv7r7q3r35u1emiooi0ao